Clover Health: Buy The Dip, Reap The Rewards

Ahmed Abdelazim
1.68K Followers
(11min)

Summary

  • Clover Health’s 32% dip following its Q3 earnings could be an opportunity to accumulate shares.
  • Clover continues to grow its top line and improve its bottom-line performance.
  • Clover’s latest star rating upgrade to 4 stars for the payment year 2026 could help it increase its market share and secure more deals for Counterpart Assistant.
  • I’m reiterating my buy rating for CLOV stock with a price target of $4.16, implying a 37% upside from current levels.

phrase buy the dip handwritten on night wet window glass surface

z1b

On November 6th, Clover Health Investments, Corp. (NASDAQ:CLOV) reported its Q3 earnings, showcasing continued top-line growth and improved bottom-line performance. Despite this, the stock is down 32% since the release of the Q3 earnings report due to missing analysts' estimates

This article was written by

1.68K Followers
As a former managing editor at a financial media publication focused on mid and small caps, I am using my experience to present investment opportunities in undervalued companies. My experience, combined with my academic background in financial markets and institutions, allows me to bring thorough research and analysis of financial statements, market trends, as well as upcoming events that may impact specific companies or industries.

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

About CLOV Stock

SymbolLast Price% Chg
Market Cap
PE
Yield
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on CLOV

Related Stocks

SymbolLast Price% Chg
CLOV
--